Q3 2019

Filed Nov 12, 2019 · 10-Q · 43 days after period end · 0001104659-19-062726

Q3 2019 · 10-Q

Revenue

$593.00K

+30.9% vs Q3 2018

Net Income

-$6.24M

N/M vs Q3 2018

EPS Diluted

-$0.01

N/M vs Q3 2018

Operating Income-$6,456,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2019	Q3 2018	Q3 2017	Q3 2016
Revenue	$593.00K	$453.00K	$148.00K	$159.00K
Net Income	-$6.24M	$12.58M	-$23.27M	-$29.23M
EPS Diluted	-$0.01	$0.02	-$0.08	-$0.28

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR